美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

334.50

+13.114.08%

成交量：7.86萬

成交額：2,567.13萬

市值：396.43億

市盈率：-201.22

高：339.00

開：320.34

低：312.22

收：321.39

52周最高：355.30

52周最低：170.99

股本：1.19億

流通股本：7,599.18萬

量比：2.37

換手率：0.10%

股息：- -

股息率：- -

每股收益(TTM):-1.6624

每股收益(LYR):-6.1240

淨資產收益率：-4.98%

總資產收益率：-1.06%

市淨率：10.51

市盈率(LYR):-54.62

資料載入中...

總覽公司新聞公告

百濟神州2025年第三季度淨利潤6.89億元

百濟神州(06160)Q3單季度營收突破百億規模上調全年業績指引

智通财经网

百濟神州：第三季度總收入達14億美元，同比增長41%

美元基金重新「殺」回中國創新藥！

麓鵬製藥IPO：成立僅7年，憑新一代BTK抑制劑挑戰禮來，後來者的野望？

医药研究社

11月，新主線——極簡投研

百濟神州有限公司通過IRAK4抑制劑與E3連接酶配體的綴合降解IRAK4及使用方法專利完成登記（有機化學專利快訊）

中國人的藥，治世界的病

港股異動 | 生物技術股走弱，榮昌生物跌近12%

老虎资讯综合

從被訴侵權到專利無效，百濟神州打贏跨國專利戰！

北京高沃知识产权

人民日報：藥品集採不是「團購」砍價

中国经济周刊

22只創新藥主題基金年內淨值增長率超50%

百濟神州更名BeOneMedicines正式生效，港股簡稱10月22日同步變更

中國創新藥，進入3.0時代

百濟神州(06160)英文股份簡稱將變更為「BEONE MEDICINES」

八年轉型深耕「耐心資本」粵開證券投出百濟神州、小鵬汽車等多個明星項目

智通港股早知道 | 現貨白銀價格「漲瘋」百濟神州(06160)索托克拉獲突破性療法認定

歷時兩年多，百濟神州打贏澤布替尼美國專利侵權訴訟

百濟神州專利案結案；*ST賽隆董事長、副總裁等辭職｜醫藥早參

每日经济新闻

百濟神州(06160)授出受限制股份單位及業績股份單位

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":334.5,"timestamp":1762442995037,"preClose":321.39,"halted":0,"volume":78551,"delay":0,"floatShares":75991800,"shares":118513677,"eps":-1.662384,"marketStatus":"交易中","change":13.11,"latestTime":"11-06 10:30:00 EST","open":320.34,"high":339,"low":312.2201,"amount":25671304.939170003,"amplitude":0.083325,"askPrice":335.49,"askSize":20,"bidPrice":334.06,"bidSize":57,"shortable":3,"etf":0,"ttmEps":-1.662384,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1762462800000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":321.39,"preHourTrading":{"tag":"盘前","latestPrice":320.12,"preClose":321.39,"latestTime":"09:29 EST","volume":7896,"amount":2546525.77368,"timestamp":1762439372095},"postHourTrading":{"tag":"盘后","latestPrice":321.39,"preClose":321.39,"latestTime":"19:58 EST","volume":2962,"amount":952087.7,"timestamp":1762390711502},"volumeRatio":2.369914,"impliedVol":0.5301,"impliedVolPercentile":0.892},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75991800,"roa":"-1.06%","roe":"-4.98%","lyrEps":-6.124009,"volumeRatio":2.369914,"shares":118513677,"dividePrice":0,"high":339,"amplitude":0.083325,"preClose":321.39,"low":312.2201,"week52Low":170.99,"pbRate":"10.51","psRate":"8.69","week52High":355.3,"institutionHeld":0,"latestPrice":334.5,"committee":0.480519,"eps":-1.662384,"divideRate":0,"volume":78551,"delay":0,"ttmEps":-1.662384,"open":320.34,"prevYearClose":184.71,"prevWeekClose":310.48,"prevMonthClose":310.48,"prevQuarterClose":340.7,"fiveDayClose":308.22,"twentyDayClose":335.8,"sixtyDayClose":307.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-11-06","symbol":"ONC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"defaultRemindTime":1762462800000,"name":null,"time":"盤後","dateTimestamp":1762405200000,"actualEps":null},{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.6667,"hold":0.0417,"sell":0.0417,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":24,"updateTime":1758171600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-11-05","current":-201.217047,"percent":0.138122,"low":-217.585346,"twenty":-89.293464,"median":-41.959228,"eighty":-24.150976,"high":-19.234246,"avg":-70.032427,"sd":62.695361,"marketCap":34039238191},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-05","current":-191.618141,"twenty":-89.293464,"median":-41.959228,"eighty":-24.150976,"marketCap":34039238191}],"updateTime":1762443000600},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581509580","title":"百濟神州2025年第三季度淨利潤6.89億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581509580","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581509580?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 20:50","pubTimestamp":1762433432,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩宋雨盈）11月6日，百济神州发布公告称，公司第三季度实现营业收入100.77亿元，同比增长41.1%；归属于母公司所有者的净利润为6.89亿元。2025年前三季度实现营业收入275.95亿元，同比增长44.2%；归属于母公司所有者的净利润为11.39亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511063557251570.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511063557251570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","06160"],"gpt_icon":0},{"id":"2581982460","title":"百濟神州(06160)Q3單季度營收突破百億規模 上調全年業績指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2581982460","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581982460?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 20:45","pubTimestamp":1762433103,"startTime":"0","endTime":"0","summary":"11月6日晚间，百济神州发布2025年第三季度A股主要财务数据公告。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251106/20251106204537_12843.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251106/20251106204537_12843.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ONC","688235","06160"],"gpt_icon":1},{"id":"2581066452","title":"百濟神州：第三季度總收入達14億美元，同比增長41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581066452","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581066452?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 19:10","pubTimestamp":1762427431,"startTime":"0","endTime":"0","summary":"百济神州(06160.HK)在港交所公告，2025年第三季度总收入达14亿美元，同比增长41%。百悦泽®（泽布替尼）该季度全球收入达10亿美元，同比增长51%。按照美国公认会计原则(GAAP)的稀释每股美国存托股份(ADS)收益为1.09美元；非GAAP稀释每股ADS收益为2.65美元。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\r\n            责任编辑：山上","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/11/06191054053997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0307460666.USD","LU2328871848.SGD","06160","688235","BK1583","BK4585","BK0239","LU1251922891.USD","BK1500","BK4526","BK1588","BK1161","LU1303224171.USD","ONC","LU0588546209.SGD","BK4139","LU1969619763.USD","LU1719994722.HKD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2581794863","title":"美元基金重新「殺」回中國創新藥！","url":"https://stock-news.laohu8.com/highlight/detail?id=2581794863","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581794863?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 08:05","pubTimestamp":1762301100,"startTime":"0","endTime":"0","summary":"据悉，在恒瑞今年四笔海外BD交易中，除德国默克外，其他三个都来自于美元基金，而这刚好揭露了一个愈发明显的行业现象，即美元基金正在重新“杀”回中国创新药。由此可见，美元基金在经历过去几年的大撤退之后，如今又重新“杀”了回来，并且势头更为迅猛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105082543a488f914&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105082543a488f914&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2097828805.USD","LU0455707207.USD","ONC","LU2328871848.SGD","LU2097828557.USD","LU2242644610.SGD","BK1574","BK1589","BK1583","LU2097828714.EUR","LU2097828631.EUR","01801","01276","LU1969619763.USD","LU0502904849.HKD","LU2097828474.EUR","06978","01877","LU2488822045.USD"],"gpt_icon":0},{"id":"2580020730","title":"麓鵬製藥IPO：成立僅7年，憑新一代BTK抑制劑挑戰禮來，後來者的野望？","url":"https://stock-news.laohu8.com/highlight/detail?id=2580020730","media":"医药研究社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580020730?lang=zh_tw&edition=fundamental","pubTime":"2025-11-04 21:14","pubTimestamp":1762262061,"startTime":"0","endTime":"0","summary":"据麓鹏制药介绍，此双重结合机制使LP-168能够同时清除携带野生型及耐药突变型BTK的肿瘤细胞，克服传统第一、二、三代BTK抑制剂因单一作用模式而产生的耐药限制。基于临床结果较为理想，麓鹏制药已于2025年5月在中国提交LP-168针对R/R MCL的新药申请。招股书显示，麓鹏制药已与翰森制药签订了合作协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104212717a6e09605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104212717a6e09605&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","03692","BK1191","BK1589","06160","ONC","BK1583"],"gpt_icon":0},{"id":"2580425750","title":"11月，新主線——極簡投研","url":"https://stock-news.laohu8.com/highlight/detail?id=2580425750","media":"每经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580425750?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 18:20","pubTimestamp":1761992400,"startTime":"0","endTime":"0","summary":"被礼来压制的诺和诺德更是开价90亿美元，想抢辉瑞的收购标的Metsera。国内的减肥药公司，之前正是因为辉瑞收购Metsera，导致市场预期的BD梦想破灭，现如今又重新燃起了希望。有量有价有故事，创新药确实有成为11月主线的感觉。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101182118a6da3e6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101182118a6da3e6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","LU0708995583.HKD","LU2242644610.SGD","06978","02359","06160","BK1574","BK1576","BK1141","LU0052750758.USD","LU2045819591.USD","LU2125910500.SGD","ONC","BK1161","LU0320764599.SGD","BK1583"],"gpt_icon":0},{"id":"2580224374","title":"百濟神州有限公司通過IRAK4抑制劑與E3連接酶配體的綴合降解IRAK4及使用方法專利完成登記（有機化學專利快訊）","url":"https://stock-news.laohu8.com/highlight/detail?id=2580224374","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580224374?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 14:24","pubTimestamp":1761978243,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025-10-31，“通过IRAK4抑制剂与E3连接酶配体的缀合降解IRAK4及使用方法”正式进入专利的公布阶段。申请人为百济神州有限公司，该项有机化学专利涉及靶向蛋白降解技术在炎症及肿瘤治疗中的应用。据专利信息显示，该双功能化合物通过将IRAK4抑制剂部分与E3连接酶配体部分缀合，实现对IRAK4蛋白的特异性募集与泛素化降解，疗效提升达显著优化。发明人为刘华庆;孙冬青;王志伟。本文披露了通过使IRAK4抑制剂部分与E3连接酶配体部分缀合而形成的新型双功能化合物及其制备方法和用途，这些双功能化合物的功能是将靶蛋白募集到E3泛素连接酶以进行降解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110114261594e87fc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110114261594e87fc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","06160","ONC","BK4139","BK4585"],"gpt_icon":0},{"id":"2580441174","title":"中國人的藥，治世界的病","url":"https://stock-news.laohu8.com/highlight/detail?id=2580441174","media":"正和岛","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580441174?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 11:30","pubTimestamp":1761967814,"startTime":"0","endTime":"0","summary":"一次符合国际标准的临床试验，成本动辄数亿美元，却是药企走向世界的必由之路。比如新冠疫情期间，国内主要用的还是布洛芬、对乙酰氨基酚等传统退烧药，真正有效的创新抗病毒药物非常少。中国的创新药，起点确实不高。数据显示，截至今年一季度，全球在研的PD-1药物中，有55%来自中国企业。中国企业基于国内生命科学和化学工程类人才优势，通过短周期分子设计与假设验证的迭代循环，在ADC等领域实现了局部“弯道超车”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101115147a480fed0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101115147a480fed0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","09995","LU2328871848.SGD","BK1161","06160","LU1969619763.USD","01530","ONC","BK1574","06978"],"gpt_icon":0},{"id":"1152404472","title":"港股異動 | 生物技術股走弱，榮昌生物跌近12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152404472","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152404472?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 13:25","pubTimestamp":1761197137,"startTime":"0","endTime":"0","summary":"10月23日，港股$生物(000504)$技术股盘中走弱，$荣昌生物(09995)$跌近12%，$药捷安康-B(02617)$跌超8%，$科伦博泰生物-B(06990)$跌超6%，$晶泰控股(02228)$、$映恩生物-B(09606)$跌近6%，$药明生物(02269)$、$康方生物(09926)$、$百济神州(06160)$跟跌。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df43def6c60d84e15ce9d1605944911d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228","06990","09606","ONC","09926","02269","09995","06160","02617"],"gpt_icon":0},{"id":"2576863022","title":"從被訴侵權到專利無效，百濟神州打贏跨國專利戰！","url":"https://stock-news.laohu8.com/highlight/detail?id=2576863022","media":"北京高沃知识产权","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576863022?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 11:03","pubTimestamp":1760929432,"startTime":"0","endTime":"0","summary":"日前，百济神州与Pharmacyclics LLC的专利侵权纠纷迎来大结局，百济神州在这场历时两年的专利战中全面胜诉，为中国药企出海提供了教科书式的应对策略。2023年10月，特拉华州法院裁定“暂缓侵权诉讼审理”，待百济神州向美国专利商标局提起的“专利授权后复审”结果出炉后，再恢复审理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020114552a6c2e122&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020114552a6c2e122&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06160","BK4585","ONC","BK4526"],"gpt_icon":0},{"id":"2576888702","title":"人民日報：藥品集採不是「團購」砍價","url":"https://stock-news.laohu8.com/highlight/detail?id=2576888702","media":"中国经济周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576888702?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 09:15","pubTimestamp":1760922952,"startTime":"0","endTime":"0","summary":"国家组织药品集采不是简单的“团购”砍价，而是用公共购买力换取更公平、更高质量的健康服务反内卷规则通过淘汰低效产能、优化资源配置，将倒逼企业转向创新药研发、工艺升级和质量提升第十一批国家组织药品集中采购将于近期开标。此次集采，企业出现超低报价的，需提供成本测算数据，并作出不低于成本报价的承诺，防止内卷和非理性报价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020092018a6c29691&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020092018a6c29691&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","BK1191","BK1515","02196","02359","01276","BK1593"],"gpt_icon":0},{"id":"2576003833","title":"22只創新藥主題基金年內淨值增長率超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576003833","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576003833?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 01:47","pubTimestamp":1760896054,"startTime":"0","endTime":"0","summary":"数据显示，截至10月19日，全市场创新药主题基金数量已增至69只，较年初的44只新增25只；总规模增至600亿元，较年初的270亿元增长了330亿元；年内业绩全部实现正增长，其中有多达22只产品年内净值增长率超过50%。从单只产品表现来看，广发中证香港创新药ETF目前在同类排名中规模最高，多达134亿元，同时年内净值增长率也接近90%，成为少有的业绩和规模双增长的产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020014737a4687d7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020014737a4687d7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","BK1574","LU0359201885.HKD","06978","BK1161","LU0359201612.USD","LU0359202008.SGD","LU1023057109.AUD","01276","ONC","LU2543165471.USD","BK1191"],"gpt_icon":0},{"id":"2576020566","title":"百濟神州更名BeOneMedicines正式生效，港股簡稱10月22日同步變更","url":"https://stock-news.laohu8.com/highlight/detail?id=2576020566","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576020566?lang=zh_tw&edition=fundamental","pubTime":"2025-10-19 16:14","pubTimestamp":1760861644,"startTime":"0","endTime":"0","summary":"10月19日，百济神州（688235/06160/BGNE）发布公告，公司英文名称已由BeiGene,Ltd.变更为BeOneMedicinesLtd.，该变更自2025年5月27日生效。同时，公司在香港联交所的股份简称将由“BEIGENE”变更为“BEONEMEDICINES”，自2025年10月22日星期三上午九时正起生效，中文股份简称仍为“百济神州”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510193538005977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","BK1583","BK4526","LU2328871848.SGD","LU1251922891.USD","BK1500","BK4139","BK1161","BK4585","ONC","06160","BK1588","LU1303224171.USD","LU1719994722.HKD","LU1770034418.SGD","LU1969619763.USD","LU0588546209.SGD"],"gpt_icon":0},{"id":"2576097460","title":"中國創新藥，進入3.0時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2576097460","media":"行舟Drug","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576097460?lang=zh_tw&edition=fundamental","pubTime":"2025-10-18 00:00","pubTimestamp":1760716858,"startTime":"0","endTime":"0","summary":"如果把“非PD-1无法融资”的扎堆时代看作1.0时代，众多品种上市但me-too大行其道看作2.0时代，当前我们或许正在进入“FIC创新+盈利”的 3.0时代。我们从JPM大会中，总结头部创新药公司（港股）的情况，以窥中国创新药产业是否到达拐点时刻。泽布替尼作为中国创新药出海的代表，已在全球70多个市场获批，已有超过100,000例患者接受了治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251018000527a6bf2347&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251018000527a6bf2347&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09688","06978","LU2488822045.USD","BK1588","BK1161","ONC","01801"],"gpt_icon":0},{"id":"2576055832","title":"百濟神州(06160)英文股份簡稱將變更為「BEONE MEDICINES」","url":"https://stock-news.laohu8.com/highlight/detail?id=2576055832","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576055832?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 21:32","pubTimestamp":1760707970,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，公司英文名称变更完成后，于香港联交所进行股份交易的英文股份简称将由“BEIGENE”变更为“BEONE MEDICINES”，自2025年10月22日星期三上午九时正(香港时间)起生效。于香港联交所进行股份交易的中文股份简称将维持不变，仍为“百济神州”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1251922891.USD","06160","BK1161","LU1770034418.SGD","LU1969619763.USD","BK1583","BK4526","BK0239","688235","BK4139","LU1719994722.HKD","LU0307460666.USD","LU1303224171.USD","LU2328871848.SGD","LU0588546209.SGD","BK1588","ONC","BK1500"],"gpt_icon":0},{"id":"2575371958","title":"八年轉型深耕「耐心資本」 粵開證券投出百濟神州、小鵬汽車等多個明星項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2575371958","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575371958?lang=zh_tw&edition=fundamental","pubTime":"2025-10-16 16:50","pubTimestamp":1760604600,"startTime":"0","endTime":"0","summary":"　　10月16日至18日，2025可持续全球领导者大会在上海世博园区召开。粤开证券董事长郭川舟受邀出席大会，并做主旨演讲。自2017年起，集团及粤开证券在战略与主营业务上实现了全面转型。他举例称，自并购粤开证券后，投资板块持续聚焦“高精尖”领域，代表性项目包括投资了科创板生物医药市值领军企业百济神州，以及小鹏汽车、文远知行等知名公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2025-10-16/doc-infuaqmp7214152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1500","161027","688235","BK1161","XPEV","BK1588","BK1119","BK1583","LU2328871848.SGD","LU1770034418.SGD","LU1251922891.USD","BK1610","LU1719994722.HKD","09868","BK4505","BK1575","BK4551","EVS.SI","BK4555","LU1969619763.USD","06160","LU0588546209.SGD","ONC","BK4585","LU1303224171.USD","LU0593848301.USD","BK4526","BK0239","BK1587","BK4139","BK4099","LU0307460666.USD","BK1539"],"gpt_icon":0},{"id":"2575390582","title":"智通港股早知道 | 現貨白銀價格「漲瘋」 百濟神州(06160)索托克拉獲突破性療法認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2575390582","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575390582?lang=zh_tw&edition=fundamental","pubTime":"2025-10-14 07:20","pubTimestamp":1760397632,"startTime":"0","endTime":"0","summary":"罕见逼空行情上演，现货白银价格“涨疯”北京时间10月14日凌晨，智通财经APP获悉，白银市场掀起近半个世纪以来罕见的逼空行情。伦敦市场流动性紧缩，直接催化了白银价格的历史性突破。白银板块涉及港股中国白银集团。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0572939691.SGD","LU0314109678.HKD","LU1807302812.USD","LU1226287792.SGD","BK1584","IE0008368742.USD","LU0880133367.SGD","06160","LU0315179316.USD","BK1521","BK1500","IE00BZ08YR35.GBP","IE0008369823.USD","LU1960683339.HKD","IE00B031HY20.USD","BK1163","01093","BK1161","LU0264606111.USD","LU1813983027.USD","IE00BZ08YS42.EUR","02577","LU1008478684.HKD","LU1951186391.HKD","LU1993786604.SGD","LU0072913022.USD","01336","LU0572940350.SGD","LU0326950275.SGD","LU0307460666.USD","BK1184","BK4526","LU1251922891.USD","BK0239","ONC","LU0501845795.SGD","LU1303224171.USD","00815","IE00BZ08YT58.USD","00666","LU1719994722.HKD","BK1116","BK1515","BK1592","BK4139","BK4585","IE00B543WZ88.USD","688235","LU2039709279.SGD","BK1583"],"gpt_icon":0},{"id":"2574311796","title":"歷時兩年多，百濟神州打贏澤布替尼美國專利侵權訴訟","url":"https://stock-news.laohu8.com/highlight/detail?id=2574311796","media":"新京报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574311796?lang=zh_tw&edition=fundamental","pubTime":"2025-10-10 10:09","pubTimestamp":1760062197,"startTime":"0","endTime":"0","summary":"10月8日晚间，百济神州发布公告，披露旗下核心BTK抑制剂泽布替尼（商品名“百悦泽”）在美国市场被诉专利侵权的最新进展：百济神州及艾伯维旗下公司Pharmacyclics公司已向法院提交一份共同协议，自愿撤回案件，案件已做出终局处理。这意味着，这场历时两年多的跨国专利侵权诉讼案，百济神州获胜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510103530492049.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510103530492049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","06160","LU0588546209.SGD","BK1583","BK4585","BK1500","LU1969619763.USD","BK4526","LU1303224171.USD","LU1770034418.SGD","LU0307460666.USD","BK1161","LU1251922891.USD","BK4139","LU2328871848.SGD","LU1719994722.HKD","BK1588"],"gpt_icon":0},{"id":"2574906759","title":"百濟神州專利案結案；*ST賽隆董事長、副總裁等辭職｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2574906759","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574906759?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 07:16","pubTimestamp":1759965397,"startTime":"0","endTime":"0","summary":"NO.1诺诚健华和Zenas就三款自免管线达成授权许可合作诺诚健华和ZenasBioPharma公司联合宣布，双方达成授权许可协议，Zenas将获得奥布替尼在多发性硬化领域的全球开发和商业化权益，以及奥布替尼在非肿瘤的其他治疗领域的开发与商业化权益。Zenas还获得两款临床前分子（一款新型口服IL-17AA/AF抑制剂和一款透脑性口服TYK2抑制剂）的相关权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510093528812936.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510093528812936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1588","LU1303224171.USD","LU0588546209.SGD","BK1500","BK4585","BK4139","BK1161","LU2328871848.SGD","BK1574","BK1515","BK4526","LU1251922891.USD","09939","06160","LU1770034418.SGD","LU1719994722.HKD","ONC","LU1969619763.USD","LU0307460666.USD","BK1583"],"gpt_icon":0},{"id":"2573300923","title":"百濟神州(06160)授出受限制股份單位及業績股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2573300923","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573300923?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 20:17","pubTimestamp":1759925822,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年9月30日，董事会薪酬委员会根据2016期权及激励计划的条款向237名承授人授出涉及合共3.6万股美国存托股份的受限制股份单位，并向一名承授人授出涉及合共2935股美国存托股份的业绩股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1719994722.HKD","LU0307460666.USD","BK1588","06160","LU0588546209.SGD","LU1251922891.USD","688235","BK1583","ONC","BK4139","LU1969619763.USD","BK1500","BK0239","LU1303224171.USD","BK4585","LU1770034418.SGD","LU2328871848.SGD","BK4526"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":192,"code":"91000000","status":"200"}]}}